Cohance Lifesciences Ltd

Stage 2 · Advancing · week 7Setup 2.5 WatchEven +0.7

Cohance Lifesciences Limited engages in the contract research, development, and manufacturing of new chemical entity (NCE) based intermediates, active pharmaceutical ingredients (API), specialty chemi… More about the company

₹455.5
-0.34% today
₹17,425 Cr · Mid cap
Market Neutral — FadingHealth Care 45.7% in Stage 2-1.4 pts / 20dPharmaceuticals 53.8%+3.8 pts
Loading price chart…
vs 52W High
-49.7%
₹279.9 lo₹904.8 hi
49.7% below 52W high
How far this stock is from its 52-week high. A pullback of 3–20% while Stage 2 structure holds is typically a better entry than chasing near the high.
Stage Maturity
Week 7
1w13w26w
Week 7 — early Stage 2, building
How long this stock has been in Stage 2. The sweet spot is mid-run — enough time to prove the structure holds, not so long it's extended. Very fresh (wk 1–4) often needs more time to confirm.
vs 200 DMA
9.5%
200 DMA: ₹416 · sloping down
Long-term trend anchor. When stock and Nifty are both above their 200 DMA, the macro backdrop supports continuation.
Rel Volume
1.10x
vs 50-day avg
Low vol (0.5–1x) on pullbacks = resting, not being sold. High vol on breakouts = commitment. Volume spike on down days is a warning sign.
Trend Health
→
MA20 flat · -0.1% vs MA50 +0.6%
Two-layer momentum read: the glyph shows whether the 20-day MA is rising (↑/↗), flat (→), or rolling over (↓). The ⇈ flag fires when the 20-day MA is pulling away from the 50-day MA — short-term momentum building on top of the longer trend. Best when both glyphs agree.
1M
-0.3%
3M
+5.7%
6M
+51.3%
YTD
-15.6%
1Y
-47.6%
Sector
Health Care
↓ Peaking
Stage 2%
45.7%
20d Δ
-1.4pp
1M return
-1.8%
3M return
+4.4%
Sector Stage-2 % · last 20 days
This stock ranks #77 of 77 Stage 2 stocks in Health Care by RS. Lagging sector peers.
Industry
Pharmaceuticals
↑ Building
Stage 2%
53.8%
20d Δ
+3.8pp
1M return
-0.9%
3M return
+3.6%
Industry Stage-2 % · last 20 days
Ranks #61 of 61 Stage 2 stocks in this industry.
Stage Cycle Timeline2025-05-08 → 2026-10-07
S? 41w
S4 10w
S1 13w
S2 6w
2025-05-082026-10-07
S1S2S3S4Setup score (0–10, dashed line at 5)
S? 41w → S4 10w → S1 13w → S4 3w → S1 1w → S2 6w current
Total tracked: 73 weeks across 6 stage runs.
Scan Membership
Breakout Watch
Latest: 2026-08-24
Stocks that stay in the scan for 13+ weeks are in the highest observed-return cohort — they keep qualifying because the structure remains intact, not by luck. Persistence in the scan is itself a quality signal.
Recent Stage Timeline
2026-10-07S2
Wk 7 · Vol 1.10x
2026-10-06S2
Wk 6 · Vol 0.42x
2026-10-05S2
Wk 6 · Vol 0.35x
2026-10-01S2
Wk 6 · Vol 0.58x
2026-09-30S2
Wk 6 · Vol 1.27x
2026-09-29S2
Wk 6 · Vol 1.28x
2026-09-28S2
Wk 5 · Vol 0.47x
2026-09-25S2
Wk 5 · Vol 0.46x
2026-09-24S2
Wk 5 · Vol 0.29x
2026-09-23S2
Wk 5 · Vol 0.93x
2026-09-22S2
Wk 5 · Vol 0.59x
2026-09-21S2
Wk 4 · Vol 8.37x
Sector Peers — Stage 2All →
KOPRAN
wk 19 · -5.0% from hi
9.0
SMSPHARMA
wk 3 · -3.0% from hi
8.7
KILITCH
wk 2 · -1.7% from hi
8.7
BAFNAPH
wk 17 · 0.0% from hi
8.6
ZIMLAB
wk 21 · 0.0% from hi
8.3
Moving averages & range
50 DMA
₹447.3
200 DMA
₹416
52W High
₹904.8
52W Low
₹279.9
5D Low
₹444
Resistance levels (recent highs)
20d High
₹461.5
60d High
₹475.6
120d High
₹493.3
250d High
₹904.8
Next resistance
+1.3%
to 20d High
Ask the Market AI about COHANCEAsk →
P/E (TTM)
91.2
Forward 33.3
Earnings Growth (YoY)
-70.3%
Revenue +77.3%
About this companyHealth Care· Pharmaceuticals

Cohance Lifesciences Limited engages in the contract research, development, and manufacturing of new chemical entity (NCE) based intermediates, active pharmaceutical ingredients (API), specialty chemicals, and formulated drugs in India, the United States, Europe, and internationally. The company offers small molecule APIs, advanced intermediates, and starting materials; antibody drug conjugates; high-purity oligonucleotide building blocks comprising phosphoramidites, nucleosides, pseudouridine, NTPs, CAP reagents, GalNAc conjugates, and fluorescent dyes; pellets and finished dosage forms; and specialty chemicals, including agrochemicals. It serves pharmaceutical, biotechnology, and chemical companies. The company was formerly known as Suven Pharmaceuticals Limited and changed its name to Cohance Lifesciences Limited in May 2025. The company was founded in 1989 and is headquartered in Hyderabad, India. Cohance Lifesciences Limited is a subsidiary of Berhyanda Limited.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-07. Past data patterns are not indicative of future results. This page is a data analytics tool only.